Myxoid Liposarcoma Clinical Trial
Official title:
A Phase 2, Single Arm, Multi Center Trial Evaluating the Efficacy of the COmbination of Sirolimus and cYclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and chOndrosarcoma
NCT number | NCT02821507 |
Other study ID # | COSYMO |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 2014 |
Est. completion date | December 2021 |
Verified date | April 2022 |
Source | Leiden University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is poor. New treatment options being evaluated and mouse models show in vivo that mammilian target of rapamycin (mTOR) inhibition can prevent tumour growth. mTOR is an kinase that is present in two complexes and thereby activates multiple pathways. Aberrant mTOR signalling is known to be involved in cancer cell survival. Several clinical studies for patients with bone or soft tissue sarcoma treated with mTOR inhibitors have been conducted and they show promising results. From these studies the investigators can conclude that the combination of an mTOR inhibitor with cyclophosphamide shows promising results in chondrosarcoma. With the lack of other treatment options for unresectable and metastatic chondrosarcoma or myxoid liposarcoma the Eurosarc consortium (www.eurosarc.eu) decided to treat these patients in a standardised way according to a common protocol with the combination of sirolimus and cyclophosphamide using the growth modulation index for evaluation in the current clinical study protocol.
Status | Completed |
Enrollment | 70 |
Est. completion date | December 2021 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Pathologically proven conventional chondrosarcoma - Or pathologically proven myxoid liposarcoma with PIK3CA mutation or Phosphatase and tensin homolog (PTEN) loss - Or pathologically proven mesenchymal or dedifferentiated chondrosarcoma - Patient is 18 years and up - Documented radiographic progression of disease according to RECIST 1.1 criteria in last 6 months - Written signed informed consent - Adequate bone marrow function (Hb = 6.0 mmol/L, absolute neutrophil count = 1.5 x 109/L, platelets = 80 x 109/L) - Availability of archival tumor material for central review or be able to perform a 3 core fresh biopsy - Ability to adhere to the study visits and all protocol requirements Exclusion Criteria: - Previously treated with an mTOR inhibitor - Known to be allergic to cyclophosphamide - Life expectancy of less than 3 months - No measurable lesions according to RECIST 1.1 - Eastern cooperative oncology group (ECOG) Performance status >2 - Major surgery less than 4 weeks prior to start of treatment - Known human immunodeficiency virus (HIV) positivity - A decreased renal function with calculated glomerular filtration rate (GFR) < 30ml/min - Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or radiotherapy to a target lesion within 21 days prior to the first dose of study drug - Pregnant or lactating women - Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localised cured prostate and cervical cancer |
Country | Name | City | State |
---|---|---|---|
Netherlands | LUMC | Leiden | |
Spain | Hospital de Sant Pau | Barcelona | |
Spain | Hospital Val d'Hebron | Barcelona | |
Spain | CIO Clara Campal | Madrid | |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Spain | Hospital Universitario y Politécnico de La Fe | Valencia | |
Spain | Instituto Valenciano de Oncología | Valencia |
Lead Sponsor | Collaborator |
---|---|
Leiden University Medical Center |
Netherlands, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The time to progression after start of treatment combination treatment of sirolimus and cyclophosphamide | 16 weeks | ||
Secondary | Comparing pre-treatment tumor material and tumor material taken during treatment using immunohistochemistry to compare activation of the pS6, Bcl-2 and mTor pathway and DNA analysis for taqman analysis to search for hotspot mutations. | 8 weeks | ||
Secondary | Register adverse events to evaluate the patient safety and tolerability of the sirolimus and cyclophosphamide combination in myxoid liposarcoma and chondrosarcoma | every 8 weeks until progression (average of 1 year) | ||
Secondary | To evaluate the response according to response evaluation criteria in solid tumors (RECIST) 1.1 | every 8 weeks until progression (average of 1 year) | ||
Secondary | Using the growth modulation index (GMI) to evaluate treatment efficiency | GMI: Time to progression during sirolimus/cyclophosphamide treatment (TTP2) divided by time to progression before start of this treatment TTP1 | every 8 weeks until progression (average of 1 year) | |
Secondary | The overall survival after start of treatment till death | every 8 weeks until progression (average of 1 year) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01957709 -
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
|
Early Phase 1 | |
Active, not recruiting |
NCT03600649 -
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
|
Phase 1 | |
Withdrawn |
NCT03397186 -
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT03989596 -
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
|
Phase 2 | |
Recruiting |
NCT04699292 -
International Prospective Registry on Local Treatment Approaches in MLS
|
||
Enrolling by invitation |
NCT05266196 -
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05492682 -
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03651375 -
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
|
Phase 2 | |
Active, not recruiting |
NCT00633165 -
Brostallicin Clinical Trial for Myxoid Liposarcoma
|
Phase 2 | |
Recruiting |
NCT04044768 -
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
|
Phase 2 | |
Active, not recruiting |
NCT03816475 -
Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)
|
Phase 2 |